Circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with olaparib plus 177lutetium-prostate specific membrane antigen-617 (177Lu-PSMA-617) in the LuPARP trial

被引：0
|
作者：
Hamid, Anis
Gupta, Santosh
Keerthikumar, Shivakumar
Pasam, Anupama
Crumbaker, Megan
Joshua, Anthony M.
Lam, Ernest
Wenstrup, Rick
Emmett, Louise
Goode, David L.
Hofman, Michael S.
Sandhu, Shahneen
机构：
[1] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[2] Univ Melbourne, Melbourne, Vic, Australia
[3] Epic Sci, San Diego, CA USA
[4] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[5] St Vincents Hosp, Sydney, NSW, Australia
[6] Peter MacCallum Canc Ctr, Mol Imaging & Therapeut Nucl Med, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5064
引用
收藏
页数：1
相关论文
共 50 条
  • [1] LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC)
    Sandhu, Shahneen
    Joshua, Anthony M.
    Emmett, Louise
    Crumbaker, Megan
    Bressel, Mathias
    Huynh, Rhonda
    Banks, Patricia Diana
    Wallace, Roslyn
    Hamid, Anis
    Inderjeeth, Andrisha Jade
    Tran, Ben
    Azad, Arun
    Alipour, Ramin
    Kong, Grace
    Kumar, Aravind Ravi
    Saghebi, Javad
    Williams, Scott
    Akhurst, Timothy J.
    Hicks, Rodney J.
    Hofman, Michael S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Molecular features of circulating tumour cells (CTCs) associate with response to 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)
    Goode, D.
    Keerthikumar, S.
    Gupta, S.
    Joshua, A. M.
    Emmett, L.
    Crumbaker, M.
    Singer, T.
    Lam, E.
    Fernandez, L.
    Jimenez, E.
    Zhang, D.
    Lin, Y.
    Wenstrup, R. J.
    Pasam, A.
    Hicks, R.
    Kong, G.
    Hamid, A.
    Sandhu, S. K.
    ANNALS OF ONCOLOGY, 2023, 34 : S988 - S989
  • [3] Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC).
    Hamid, Anis
    Hofman, Michael S.
    Bressel, Mathias
    Emmett, Louise
    Joshua, Anthony M.
    Spain, Lavinia Anne
    Horvath, Lisa
    Crumbaker, Megan
    Pasam, Anupama
    Callahan, Jason
    Tubbs, Alisa
    Fernandez, Luisa
    Wenstrup, Richard J.
    Kong, Grace
    Lewin, Jeremy Howard
    Tran, Ben
    Azad, Arun
    Schonhoft, Joseph D.
    Hicks, Rodney J.
    Sandhu, Shahneen
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] The Auckland experience with Lutetium-177 prostate-specific membrane antigen (177LU-PSMA-617) in advanced, metastatic castration-resistant prostate cancer (mCRPC): 2018-2020
    Hitchen, Nadia
    Waldron, Nick
    Lawrence, Nicola
    Fu, Simon
    Jacobs, Carmel
    Hanning, Fritha
    Lim, Remy
    Fong, Peter
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 67 - 67
  • [5] Comment on, 177Lu-PSMA-617 in metastatic, castration-resistant prostate cancer"
    Radtke, Jan Philipp
    Albers, Peter
    Giesel, Frederik Lars
    AKTUELLE UROLOGIE, 2022, 53 (02)
  • [6] Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
    Sun, Michael
    Niaz, Muhammad O.
    Nelson, Adlai
    Skafida, Myrto
    Niaz, Muhammad J.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (06)
  • [7] VISION trial: 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer
    Rohith, Gorrepati
    INDIAN JOURNAL OF UROLOGY, 2021, 37 (04) : 372 - 373
  • [8] 177Lu-PSMA-617 Therapy in a Case of Metastatic Castration-Resistant Prostate Cancer
    Qu, Gengcuo
    Hua, Qingchu
    Li, Hongmei
    Zhang, Yu
    Chen, Yue
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (02) : 152 - 153
  • [9] PRINCE: Phase I trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Sandhu, Shahneen
    Joshua, Anthony M.
    Emmett, Louise
    Spain, Lavinia Anne
    Horvath, Lisa
    Crumbaker, Megan
    Anton, Angelyn
    Wallace, Roslyn
    Pasam, Anupama
    Bressel, Mathias
    Cassidy, Erin
    Banks, Patricia
    Dhiantravan, Nattakorn
    Akhurst, Timothy J.
    Kumar, Aravind Ravi
    Alipour, Ramin
    Scalzo, Mark
    Williams, Scott
    Hicks, Rodney
    Hofman, Michael S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] Real world outcomes of 177Lu-PSMA-617 PSMA in a racially diverse cohort of patients with metastatic castration resistant prostate cancer (mCRPC).
    Gerke, Margo
    Marra, Angelo
    Liu, Yuan
    Muzahir, Saima
    Brown, Jacqueline T.
    Nazha, Bassel
    Berchuck, Jacob E.
    Parikh, Ravi Bharat
    Ciuro, Jordan Alana
    Hartman, Caitlin
    Mcclintock, Greta Russler
    Caulfield, Sarah
    Kucuk, Omer
    Carthon, Bradley Curtis
    Schuster, David M.
    Bilen, Mehmet Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
12345